| Rachel Marie Garcia, NP | |
|
950 N 19th St Ste 100, Abilene, TX 79601-2420 | |
| (325) 670-7187 | |
| Not Available |
| Full Name | Rachel Marie Garcia |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 3 Years |
| Location | 950 N 19th St Ste 100, Abilene, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376298315 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | 787685 (Texas) | Secondary |
| 363LF0000X | Nurse Practitioner - Family | 1072782 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hendrick Medical Center | Abilene, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hendrick Provider Network | 9739162181 | 231 |
| The West Texas Rehabilitation Center | 2860301215 | 361 |
News Archive
Duke University biologists have evolved a complex trait in the laboratory - using the pressure of selection to induce tobacco hornworms to evolve the dual trait of turning black or green depending on the temperature during their development.
In this volume an international group of basic and clinical investigators presents their latest research on neuroendocrine physiology, advances in the control of the onset of puberty and its disorders, and basic and clinical aspects of the GH/IGF-1 and hypothalamic-pituitary-adrenal axes. An entire section is dedicated to pituitary tumors, including genetics and neuroimaging, and another covers the neuroendocrine control of substrate metabolism, including hypothalamic obesity and anorexia.
More than one third of Americans are considered obese and approximately 15 million (5%) Americans now have a body mass index greater than 40. The April issue of the Journal of the American Dietetic Association focuses on the ever-increasing use of bariatric surgery to control the excess morbidity and mortality associated with extreme obesity and the important role that registered dietitians play in the management of patients who have undergone the procedure.
InflaRx announced today the successful completion of its recent clinical phase I study investigating its lead drug candidate IFX-1, a new first in class monoclonal antibody inhibiting complement driven inflammation. The trial reached its anticipated endpoints, demonstrating that IFX-1 is safe and well tolerated while displaying desirable PK and PD parameters.
Researchers have shown that patients who receive trastuzumab at the same time as post-chemotherapy radiation treatments for HER-2 positive breast cancer have no more risk for major side effects or complications than those who do not receive the drug.
› Verified 2 days ago
| Entity Name | Hendrick Provider Network |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396961322 PECOS PAC ID: 9739162181 Enrollment ID: O20040609001047 |
News Archive
Duke University biologists have evolved a complex trait in the laboratory - using the pressure of selection to induce tobacco hornworms to evolve the dual trait of turning black or green depending on the temperature during their development.
In this volume an international group of basic and clinical investigators presents their latest research on neuroendocrine physiology, advances in the control of the onset of puberty and its disorders, and basic and clinical aspects of the GH/IGF-1 and hypothalamic-pituitary-adrenal axes. An entire section is dedicated to pituitary tumors, including genetics and neuroimaging, and another covers the neuroendocrine control of substrate metabolism, including hypothalamic obesity and anorexia.
More than one third of Americans are considered obese and approximately 15 million (5%) Americans now have a body mass index greater than 40. The April issue of the Journal of the American Dietetic Association focuses on the ever-increasing use of bariatric surgery to control the excess morbidity and mortality associated with extreme obesity and the important role that registered dietitians play in the management of patients who have undergone the procedure.
InflaRx announced today the successful completion of its recent clinical phase I study investigating its lead drug candidate IFX-1, a new first in class monoclonal antibody inhibiting complement driven inflammation. The trial reached its anticipated endpoints, demonstrating that IFX-1 is safe and well tolerated while displaying desirable PK and PD parameters.
Researchers have shown that patients who receive trastuzumab at the same time as post-chemotherapy radiation treatments for HER-2 positive breast cancer have no more risk for major side effects or complications than those who do not receive the drug.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Rachel Marie Garcia, NP 950 N 19th St Ste 100, Abilene, TX 79601-2420 Ph: (325) 670-7187 | Rachel Marie Garcia, NP 950 N 19th St Ste 100, Abilene, TX 79601-2420 Ph: (325) 670-7187 |
News Archive
Duke University biologists have evolved a complex trait in the laboratory - using the pressure of selection to induce tobacco hornworms to evolve the dual trait of turning black or green depending on the temperature during their development.
In this volume an international group of basic and clinical investigators presents their latest research on neuroendocrine physiology, advances in the control of the onset of puberty and its disorders, and basic and clinical aspects of the GH/IGF-1 and hypothalamic-pituitary-adrenal axes. An entire section is dedicated to pituitary tumors, including genetics and neuroimaging, and another covers the neuroendocrine control of substrate metabolism, including hypothalamic obesity and anorexia.
More than one third of Americans are considered obese and approximately 15 million (5%) Americans now have a body mass index greater than 40. The April issue of the Journal of the American Dietetic Association focuses on the ever-increasing use of bariatric surgery to control the excess morbidity and mortality associated with extreme obesity and the important role that registered dietitians play in the management of patients who have undergone the procedure.
InflaRx announced today the successful completion of its recent clinical phase I study investigating its lead drug candidate IFX-1, a new first in class monoclonal antibody inhibiting complement driven inflammation. The trial reached its anticipated endpoints, demonstrating that IFX-1 is safe and well tolerated while displaying desirable PK and PD parameters.
Researchers have shown that patients who receive trastuzumab at the same time as post-chemotherapy radiation treatments for HER-2 positive breast cancer have no more risk for major side effects or complications than those who do not receive the drug.
› Verified 2 days ago
Jewel Monique Trancoso, APRN, FNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2600 Ivanhoe Ln Apt 204, Abilene, TX 79605 Phone: 325-513-7293 | |
Brandon M. Goetz, N.P. Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1900 Pine St, Abilene, TX 79601 Phone: 325-670-2151 Fax: 405-321-4603 | |
Ana Maria Argumaniz, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1749 Pine St, Abilene, TX 79601 Phone: 325-696-0600 | |
Lauren Brooke Terrell, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 950 N 19th St Ste 200, Abilene, TX 79601 Phone: 325-670-5320 Fax: 325-670-5324 | |
Ms. Elizabeth Webber, FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 818 Lexington Ave, Abilene, TX 79605 Phone: 325-696-0212 | |
Richard Sankara Musonera, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1749 Pine St, Abilene, TX 79601 Phone: 325-696-0600 Fax: 325-676-3873 | |
Bailey Ann Estes, APRN-CNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1210 N 18th St, Abilene, TX 79601 Phone: 325-207-4734 |